Background: Very effective trastuzumab-based primary systemic therapy (PST) can be proposed for conservative surgery purpose to human epidermal growth factor receptor 2 (HER2)-positive breast cancer (HER2+BC). Long-term follow-up (LTFU) warrants further data. Conclusion: This is the first report of LTFU showing that anthracycline-free trastuzumab-based PST combined either with docetaxel and/or carboplatin can achieve, without cardiac toxicity, very competitive results in terms of pathological complete response, RFS and OS, in HER2+BC. The choice of this schedule could be proposed to patients with vascular contraindication for anthracyclines or because patient's or physician's preference for a taxane-only schedule.
introduction
Primary systemic chemotherapy (PST) is the treatment of choice for women with locally advanced breast cancer [1] . It aims to reduce the tumor size and may allow for breast conserving surgery. Tumor response can be assessed clinically and pathologically and is valuable for testing new therapies. Pathological complete response (pCR) also provides a surrogate marker for disease-free survival (DFS) and overall survival (OS) [2] .
Here, we report the long-term results of 135 women with human epidermal growth factor receptor 2 (HER2)-overexpressing stage II/III breast cancer treated with anthracycline-free trastuzumab (Herceptin 
Bristol Myers Squibb, Paris, France). Most of the patients were initially included in two phase II trial of trastuzumab-based PST [3, 4] .
The rationale for integrating trastuzumab into PST for HER2-positive breast cancer was based on the association between HER2 overexpression and poor prognosis [5] [6] [7] [8] that can partially be reversed by trastuzumab, which provides significant clinical benefits including a survival advantage when combined with standard chemotherapy in HER2-positive breast cancer either in the metastatic [9, 10] or in the adjuvant [11] [12] [13] settings and has a favorable safety and tolerability profile especially in anthracycline-free patients.
patients and methods
Long-term follow-up (LTFU) was studied in two cohorts of patients receiving trastuzumab-based PST with pathological complete response as primary end point ( Figure 1 ). The first cohort of patients corresponded to 64 patients treated with trastuzumab and docetaxel and assessable for LTFU. Briefly, these patients received trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly and 3-weekly docetaxel for six cycles before surgery (TH regimen). Three-weekly trastuzumab [trastuzumab 8 mg/kg (day 1), followed by 6 mg/kg 3-weekly] [14] and adjuvant trastuzumab for a total of 18 injections were administered in the 25 most recent patients when the results of the major adjuvant trials [11] [12] [13] were known. The second cohort corresponded to 70 patients treated with trastuzumab, docetaxel and carboplatin and assessable for LTFU. Briefly, these patients received trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly plus 3-weekly docetaxel 75 mg/m 2 , and carboplatin area under curve 6 for six cycles before surgery (TCH regimen). Adjuvant trastuzumab was also administered for a total of 18 injections. In the two cohorts, surgery and axillary nodes dissection were mandatory while adjuvant radiotherapy was administered according to institutional practice and post-surgical hormonal therapy was systematic in patients with hormonereceptor-positive tumors.
All statistical analyses were carried out with a bilateral alpha type one error of 5%.
Relapse-free survival (RFS) was defined as time interval from the date of histology until the date of first relapse (local, regional or metastatic relapse) or death (all causes), whichever come first. Alive patients without relapse were censored at the last follow-up. OS was defined as time interval from the date of histology until death (all causes).
Survival curves were estimated using Kaplan-Meier methods and compared by log-rank test. Median follow-up was calculated using reverse Kaplan-Meier method. Univariate and multivariate Cox proportional hazards model were done to calculate hazard ratios (HRs) and its 95% confidence intervals (CIs). Multivariate analysis was carried out on variables potentially predictive of the risk to recur or death in 20% threshold univariate analysis. The method of Backward was used to maximize the level of multivariate prediction model. The threshold output was set at 15%. The P values of <0.05 were considered to indicate statistical significance.
results
LTFU data were available for 135 patients (Figure 1) . Sixty-four patients (47.4%) received neoadjuvant TH, from whom 25 also received adjuvant trastuzumab. Seventy-one patients (52.6%) received neoadjuvant TCH from whom 66 received also adjuvant trastuzumab. Tumor characteristics and response to PST (Chevallier grade) [15] are given in Table 1 . The global rate of pCR with or without remaining in situ carcinoma (Chevallier grade 1/2) was 39.39% (52/132) in the global population. Surgery data were available in 128 patients. Surgery was breast conservative in 82 (64%).
The median follow-up was 48.3 months (95% CI 45.3-52.4 months).
During the follow-up, 33 (24.44%) patients presented a relapse of the disease. At 48 months, the RFS rate was 73.2% (95% CI 63.76% to 80.55%) (Figure 2A ). Cox univariate analysis showed that the RFS was neither influenced by the type During the follow-up, 13 (9.92%) patients died of their disease. At 48 months, the OS rate was 91.87% (95% CI 84.23% to 95.90%) ( Figure 2B ). Cox univariate analysis showed that the OS was neither influenced by the type of neoadjuvant chemotherapy (TH or TCH) (P = 0.158) nor by the SBR grade (P = 0.27) nor by the hormone receptor status (P = 0.08) nor by the pathological tumor size (P = 0.92) nor by the Chevallier grade (P = 0.38) nor by the adjuvant trastuzumab (P = 0.21). The pathological nodal invasion (HR = 4.91, 95% CI 1476-16.36, P = 0.0095) could unfavorably influence the OS (Table 3 ) ( Figure 3B ). The OS Cox multivariate analysis could not be carried out because of the lack of events.
Cardiac toxicity was minor in the 135 patients. Three (2.2%) transient, reversible asymptomatic decrease in left ventricular ejection fraction (LVEF) were noted. Treatment was generally well tolerated. Febrile neutropenia was more frequent with TH than with TCH. Other toxic effects were those usually encountered with either docetaxel or trastuzumab or carboplatin.
discussion
PST is now frequently used for selected patients with operable disease to facilitate breast conservation [16] . In patients with HER2-positive breast cancer, anthracycline-and trastuzumabbased PST is superior to non-trastuzumab-based PST in terms of clinical or pathologically documented response and survival [17] [18] [19] [20] . This study shows that anthracycline-free trastuzumabbased PST combined either with docetaxel 100 mg/m 2 or with docetaxel and carboplatin is also active in women with HER2-overexpressing primary breast cancer with >39% pCR. Moreover, after six cycles of trastuzumab-based PST, adequate locoregional therapy, hormonal therapy in patients with hormone-receptor-positive tumors and adjuvant trastuzumab, 48 months of LTFU can demonstrate very interesting 73.2% RFS rate and 91.9% OS rate.
These survival results compare favorably with several other phase II or phase III studies that have evaluated PST with trastuzumab in combination with cytotoxic therapy but very few of them have reported LTFU [17, 18, 21, 22] .
Buzdar et al. [17] reported that the addition of trastuzumab to paclitaxel (Taxol) followed by fluorouracil/epirubicin/ cyclophosphamide (FEC) chemotherapy was superior to paclitaxel and FEC alone, providing a pCR of 65% versus 26%, respectively (P = 0.016). The median follow-up was 36.1 months (range, 12.3-54.8 months). DFS was significantly better among patients randomly allocated to chemotherapy plus trastuzumab compared with patients randomly allocated to chemotherapy alone (P = 0.04). There has been no recurrent disease in the patients randomly allocated to chemotherapy plus trastuzumab, and the estimated DFS at both 1 and 3 years was 100% (1-year DFS estimate: 95% CI 85.2-100) [18] .
Hurley et al. [21] demonstrated that 12 weeks of neoadjuvant docetaxel, cisplatin and trastuzumab with filgrastim, followed by surgery, adjuvant doxorubicin and cyclophosphamide and locoregional radiotherapy with or without tamoxifen were active in HER2-positive breast cancer. pCR rates in breast and axilla reached 22%. At a median follow-up time of 43 months, 4-year progression-free survival 
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rate was 81% (95% CI 64% to 90%) and OS rate was 86% (95% CI 71% to 94%). Gianni et al. [19] recently published the efficacy analysis of the International randomized phase III NOAH trial. In patients with HER2-positive tumors, the addition of trastuzumab to anthracycline-and paclitaxel-containing chemotherapy followed by combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil, for a total of 10 courses, was superior to the same chemotherapy alone in terms of pCR, event-free survival and OS. After 3.2 years of follow-up, event-free survival rate was 71% and OS rate was 87%.
Shimizu et al. [22] , in a retrospective analysis of 125 patients, showed that the addition of trastuzumab to an anthracycline-taxane PST lead to an increase in pCR (50% versus 24%) but did not yield a significant difference in DFS (92% and 78% for 1-and 2-year DFS rates, respectively).
The results presented here are also interesting because they were obtained without any use of anthracycline and with minor Since the first studies, in the metastatic setting, trastuzumab cardiac toxicity has been highlighted especially when trastuzumab was combined with anthracycline or used after anthracycline [10] . Severe cardiac events can occur in 2% firstline trastuzumab alone or combined with paclitaxel and in 16% trastuzumab treatment when combined with anthracycline [23] . In the large adjuvant trials [12, 13, 24, 25] , cardiac event rate was highest in the anthracycline-containing trastuzumab arms (1.9%-3.8%) and lowest in the regimen of docetaxel, carboplatin and trastuzumab (0.4%) [26] . In the PACS-04 trial, cardiac toxicity during anthracycline-based chemotherapy and cardiac toxicity during trastuzumab treatment lead to trastuzumab under treatment in 46 patients (18%) [27] .
These data are, somehow, contra balanced by the concomitant use of anthracycline and trastuzumab, in anthracycline-free patients, during the neoadjuvant setting. In the study of Buzdar et al., no cardiac safety concerns were observed either during the treatment phase or during the follow-up. No congestive cardiac failure was observed. Equivalent numbers of ejection fraction decrease were observed with or without trastuzumab. In the extended phase II study, one patient treated by trastuzumab and chemotherapy developed a grade 1 cardiac dysfunction. The exact binomial 95% CI of the probability of cardiac failure was 0% to 7.87% [17, 18] . In the Gianni et al. study, cardiac events were noted in 11% of the population, independently from the addition of trastuzumab. Worst LVEF (National Cancer Institute -Common Toxicity Criteria grade 1, 2 or 3) were noted more frequently in the chemotherapy and trastuzumab arm for 23%, 2% and 2% of the patient, respectively, than in the chemotherapy-only arm for 16%, 1% and 0% of the patients, respectively [19] . More recently, Untch et al. using, in 455 patients, neoadjuvant trastuzumab associated with epirubicin 90 and cyclophosphamide for four cycles then associated with docetaxel and/or capecitabine described a symptomatic congestive heart failure grade 3 in one patient, a cardiac ischemia grade 2 in one patient, a syncope grade 3 in one patient and an asymptomatic LVEF decrease in four patients. Symptomatic cardiac events occurred therefore in only 0.6% of the patients [20] . Should the usual contraindication of concomitant use of trastuzumab and anthracyclines, outside clinical trials [16] , be modified according to these new data is not known. However, after these publications, the addition of anthracycline to trastuzumab seems safe.
The role of anthracycline in the neoadjuvant setting of HER2-positive tumors has never been tested in a randomized study. pCR results, with anthracycline-and trastuzumab-based chemotherapy, are very variable in small series, starting from 7% [28] up to 75% [29] . In larger series, pCR could reach 34% [20] or 38% [19] or 65% [17] . The anthracycline-free chemotherapy used in the present study cannot be considered as a standard of treatment because until now anthracycline + taxane chemotherapies have given the best long-term results [30] . However, Slamon et al. have presented the BCIRG-006 study analysis testing the adjuvant role of trastuzumab in patients with HER2-positive tumors. Trastuzumab gives the patients a significant reduction of the risk of recurrence and of the risk of death. The results are not significantly different whether anthracycline is used or not [25] . More data are needed to know the exact role of anthracycline in the neoadjuvant treatment of HER2-positive tumors.
Despite it was not in the scope of this study, univariate analysis of RFS showed adjuvant trastuzumab use as a factor of better prognosis. This is in accordance with the major adjuvant studies [11] [12] [13] . The same result was not found for OS but probably due to the relatively small population studied here and to the lack of death events.
Univariate analysis did not demonstrate that Chevallier grade 1 or 2, corresponding to a complete disappearance of invasive carcinoma either in the tumor or in the nodes, was a factor of better RFS or of better global survival. The role of pCR in OS for breast cancer patient treated with PST is still contradictory [31, 32] . In HER2-positive tumors, additionally to the tumors completely eradicated after trastuzumab-based therapy, a great number of the tumors do present a major clinical and histological response (96% in the TAXHER trial [3] and 95% in the GETN(A) trial [4] ) with only few residual carcinoma cells making the pCR role in prognosis difficult to demonstrate. Additionally, if HER2 positivity is a major factor of response to trastuzumab [33, 34] , HER2 positivity could be also a factor of relapse and the association between pCR rate and RFS gives 
conflicting results, being sometimes statistically associated [18] but sometimes not [21, 22] . Multivariate analysis of RFS showed that RFS was worse when persistent nodal invasion was diagnosed after surgery. Since a long time, persistent nodal invasion after PST has been recognized as a strong and negative factor of survival [35, 36] . However, more refined prognostic score after PST is under development [37] .
In conclusion, this is the first report of LTFU showing that anthracycline-free trastuzumab-based PST combined either with docetaxel or with docetaxel and carboplatin can achieve, without cardiac toxicity, very competitive results in terms of pCR, RFS and OS, in stage II or III HER2-positive breast cancer. The choice of this schedule could be proposed to patients with vascular contraindication for anthracyclines or because patient's or physician's preference for a taxane-only schedule. Overall Survival A B Figure 3 . Relapse-free survival (A) and overall survival (B) of 135 patients with human epidermal growth factor receptor 2-positive breast cancer treated with anthracycline-free trastuzumab-based preoperative systemic therapy combined either with docetaxel or with docetaxel and carboplatin, according to pathological node invasion (pN0, no nodal invasion; pN1, positive nodal invasion). Survival curves were estimated using Kaplan-Meier methods and compared by log-rank test. 
